Abivax
↗Paris, France
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company's lead drug candidate, obefazimod (ABX464), is a first-in-class oral small molecule that enhances the expression of microRNA-124, a natural regulator of the inflammatory response.
Headquartered in Paris with a significant US presence, Abivax is currently transitioning toward a commercial-stage entity. Its primary focus is on inflammatory bowel diseases (IBD), specifically ulcerative colitis and Crohn's disease. The company has recently experienced a massive market valuation surge following positive Phase 3 data and is a subject of significant acquisition interest from major pharmaceutical players.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$5M-$10M
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$1.2B
Investors:Truffle Capital, Heights Capital Management, Kreos Capital, Claret European Growth Capital, Sofinnova Partners, 5AM Ventures
STOCK
Exchange:NASDAQ
Ticker:ABVX
Market Cap:$9.6B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Ulcerative Colitis)
Modalities:Small molecule, miR-124 enhancer
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Abivax LLC (USA)
Key Partnerships:LifeSci Communications (Media), NewCap (Investor Relations)
COMPETITION
Position:Emerging
Competitors:Eli Lilly (Omvoh), Pfizer (Velsipity), Bristol Myers Squibb (Zeposia), AbbVie (Rinvoq), Takeda (Entyvio)
LEADERSHIP
Key Executives:
Marc de Garidel - CEO
Didier Blondel - CFO
Fabio Cataldi - CMO
Scientific Founders:Philippe Pouletty
Board Members:Sylvie Grégoire (Chair), Marc de Garidel, June Lee, Troy Ignelzi, Camilla Soenderby
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Abivax. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.